Updates on immunotherapy in non-small cell lung cancer

Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab

“…Our approach, that proved to be well tolerated, is broadly useful and highly appealing because: first it will make possible to simultaneously block internalization of multiple tumorigenic receptors (i.e. EGFR, ErbB2, ErbB3 and cMet) that are all of therapeutic value in lung cancer [ 45 , 46 ], thus representing a precious tool to counteract tumor resistance to single agent therapies; second, it will allow the delivery of diverse, multiple, patient-tailored, biotinylated therapeutics, possibly combining anti-tumor drugs with immune-stimulating reagents like IL2 [ 47 ] or anti-CTLA4, anti-PD-1 antibodies [ 48 ] thus offering a unique opportunity for an integrated fight against lung cancer, with or without concurrent chemotherapy. In this respect, here we show that AvidinOX anchoring does not interfere with Cetuximab capability to induce ADCC; third, much better tolerability is expected compared to intravenous antibody treatments due to low doses and no systemic exposure; fourth, applicability could be easily extended to lung metastases from any cancer for which therapeutic antibodies are available; last but not least, AvidinOX is not expensive and the amount of expensive antibodies is expected to be so low that the therapy will be certainly affordable for any patient.…”

Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer

“…Targeted antibodies act against specific tumor features or tumor-promoting mechanisms. Antibody-based therapy has revolutionized the standard of antitumor therapy in melanoma and lung cancer (26)(27)(28). The efficacy of antibody-based therapy was also shown for multiple other cancer entities such as renal cancer, bladder cancer and head and neck cancer (25).…”

Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis

“…In 2011, a CTLA-4 immune checkpoint inhibitor, ipilimumab, was approved for metastatic melanoma treatment (20,21). From 2014, PD-1/PD-L1immune checkpoint inhibitors were approved for different cancers including lung cancer, kidney cancer, urothelial carcinoma, Hodgkin's disease, breast cancer, as well as for microsatellite high and deficient solid tumors mismatch repair (22)(23)(24). However, Sip-T remains the only immunotherapy approved for PCa treatment.…”